Navigation Links
Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies
Date:4/25/2013

SAN DIEGO, April 25, 2013 /PRNewswire/ -- Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the following statement:

Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity. With obesity contributing over $200 billion annually to healthcare spending, Orexigen agrees that policymakers need thorough budgetary analyses that capture short and long-term impacts of obesity policy. A longer view may enable policymakers to have more information when making legislative decisions. Brill noted that the largest budgetary benefits from reducing the burden of obesity would be federal savings within the Medicare and Medicaid programs that would result from avoiding obesity-related diseases and co-morbidity.

"Today's report supports our belief that, while there are substantial near-term benefits of weight loss for obese patients, an even larger value should accrue to individuals and societies when health improvements are assessed over a longer period of time," said Orexigen CEO, Michael Narachi .

The report's author, Alex Brill , is a Research Fellow at the American Enterprise Institute and formerly counsel to the Simpson-Bowles Deficit Reduction Commission and chief economist and policy director to the House Ways and Means Committee. Mr. Brill also served on the President's Council of Economic Advisers under President George W. Bush . Mr. Brill has worked on a variety of economic and legislative policy issues, including dividend taxation, the alternative minimum tax, international tax policy, social security reform, defined benefit pension reform and U.S. trade policy.

The report may be found at the Campaign to End Obesity's website http://obesitycampaign.org/research.asp

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Contact: McDavid Stilwell , 858-875-8600

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
2. Orexigen Therapeutics to Present at Upcoming Conferences
3. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
4. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
5. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
6. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
7. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
8. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
9. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
10. Aratana Therapeutics Adds To Drug Development Team
11. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
Breaking Biology News(10 mins):